Full-Time

Head of Computational Drug Design

Isomorphic Labs

Isomorphic Labs

201-500 employees

AI-powered drug discovery and development

No salary listed

Cambridge, MA, USA

Hybrid

Hybrid: must be in-office 3 days per week (Tue, Wed, and one other day).

Category
Biology & Biotech (4)
, , ,
Required Skills
Python
Neural Networks
Machine Learning
Requirements
  • PhD in Computational Chemistry, Medicinal Chemistry, Synthetic Chemistry, or a related scientific field, or equivalent industrial experience.
  • Solid foundation in computational chemistry with a minimum of 10+ years previous industrial experience within a pharma/biotech/CRO setting.
  • Proven experience leading computational chemistry strategy and execution for multiple drug discovery programs and target classes, and managing high-performing scientific teams.
  • Prior experience of leading drug discovery programs, from hit finding to lead optimisation and candidate selection.
  • Strong expertise in virtual screening, ligand and structure-based drug design using physics-based and ideally AI/ML methods.
  • Proven track record of developing models using ML or deep learning methods.
  • Expertise in writing and implementing Python scripts for analysis and tool development, and/or utilising pipelining tools to support cheminformatics and design workflows.
  • Genuine passion and enthusiasm for applying AI/ML to drug design and how this can transform the field.
  • Demonstrated success managing external collaborations (industry/CROs) and working effectively in cross-functional environments.
  • Growth mindset, adaptability, and eagerness to learn new concepts and techniques.
Responsibilities
  • Apply your knowledge and track record of modern drug design and discovery principles to deliver our Drug Design portfolio.
  • Provide direct line management for a growing team of Computational Chemists. Set clear goals, provide regular feedback, support their professional development, and foster a collaborative and high-performance team environment.
  • Provide strategic input and technical direction to our AI/ML platform teams.
  • Collaborate both internally and with third party organisations, interacting within multidisciplinary teams, to support data-driven delivery of high quality scientific solutions to complex technical problems.
  • Represent the company externally, interacting with existing and prospective collaborators and Contract Research Organizations (CROs).
  • Prepare detailed scientific proposals and reports to support new and ongoing programs.
  • Embrace and champion our culture of inclusion and continuous professional development.
Desired Qualifications
  • Prior experience leveraging machine learning and generative AI methods for hit finding (e.g. ultra-large virtual screening and active learning), molecular design and lead optimisation
  • Strong knowledge of drug design principles, including ADMET and DMPK.
  • Knowledge of modalities such as PROTACs, molecular glues, PPI inhibitors or ADCs.
  • A track record of authorship of relevant scientific manuscripts.

Isomorphic Labs uses artificial intelligence to speed up drug discovery and development. It applies machine learning and computational methods—building predictive and generative models—to accelerate how drugs are designed and how medical research is conducted. The company differentiates itself by combining the AI breakthroughs from Google DeepMind with Alphabet backing, enabling fast experimentation and scaling across biology while maintaining startup-style agility. Its goal is to bring safer, more effective therapies to market more quickly by advancing AI-driven medicine using deep learning, reinforcement learning, and other advanced techniques.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$2.6B

Headquarters

London, United Kingdom

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Advancing AI-designed drugs to human trials in oncology and immunology via Eli Lilly, Novartis partnerships.
  • Nearing $2 billion funding round after $600 million raise led by Thrive Capital in April 2025.
  • Appointing Dr. Ben Wolf as CMO establishes US presence for clinical expansion.

What critics are saying

  • Exscientia gains first AI-drug approval in Phase III trials March 2026, diverting Eli Lilly partnerships.
  • FDA March 2026 guidance mandates 5-year data, halting IsoDDE trials without $500M wet-lab spend.
  • OpenAI o1-pro with Sanofi data outperforms IsoDDE by 25% on affinities per January 2026 benchmarks.

What makes Isomorphic Labs unique

  • IsoDDE doubles AlphaFold 3 accuracy on protein-ligand benchmarks announced February 2026.
  • IsoDDE identifies novel binding pockets from amino acid sequences in seconds.
  • Proprietary models predict binding affinities exceeding physics-based methods at fraction of cost.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Isomorphic Labs who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

1%
Isomorphic Labs
Jun 17th, 2025
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence.

Forbes
Jun 11th, 2025
Nvidia Announces Massive New Initiatives In Pharma And Clinical Research

Nvidia has quickly become a leader in the AI ecosystem. NurPhoto via Getty ImagesFounder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company’s work in healthcare and life-sciences.The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation’s (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline.Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia’s computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings.The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces

BW Healthcare World
Jun 2nd, 2025
Isomorphic Labs Raises $600M in Q1 2025

UK biopharma venture financing surged to $1.1 billion in Q1 2025, doubling from $550 million in Q4 2024, driven by Isomorphic Labs' $600 million and Verdiva Bio's $411 million rounds. Despite global downturns, UK investment rose from $827 million in 2022 to $1.7 billion in 2024. However, US investors funded most of Q1 2025's total, highlighting reliance on overseas capital. UK initiatives aim to boost domestic investment, but upcoming drug-pricing policy changes may increase costs.

Labiotech.eu
Apr 24th, 2025
21 Uk Biotech Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023 started an upward trajectory, the UK biotech scene is now one of the most vibrant in Europe, laying the foundation for numerous companies to develop innovative technologies, some of which have spun out of the nation’s most prestigious universities. In this article, we take a look at 21 UK biotech companies you should know about. Amphista Therapeutics Disease areas: Oncology and neurologyTechnology: Targeted protein degradationRecent news: Unveiled new data demonstrating the potential of its protein degraders in animal modelsAmphista Therapeutics is focused on transforming the lives of patients with severe diseases, with a particular focus on cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). Its next-generation bifunctional molecules use a novel approach that makes use of a wider range of the body’s own innate protein degrading mechanisms than those used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches – such as those associated with the use of a narrow range of protein degrading mechanisms – providing the opportunity to treat a wider range of diseases. In May 2023, the UK biotech company announced that it had achieved its first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb

Sifted
Apr 16th, 2025
Isomorphic Labs raises $600m in Q1

In Q1, European startups raised €12.8 billion, with healthtech leading, including Isomorphic Labs' $600 million raise. AI agent startups also saw significant investment, with 61 deals totaling €827 million. Despite fewer deals, larger rounds were common, with a median equity deal size of €3 million. Debt funding reached €4 billion. Four new unicorns emerged, including Tines and Neko Health. The UK led in equity fundraising, while Ireland and Spain showed strong growth.